Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precision Cell Immunotherapy (Ningbo Cancer Hospital)
- Development stage
- Phase 2
- Lead developer
- Ningbo Cancer Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intradermal
01
Overview
Precision Cell Immunotherapy is an autologous, multi-component cell-based treatment developed by Ningbo Cancer Hospital for the treatment of advanced hepatocellular carcinoma (HCC). The therapeutic regimen integrates three distinct cell types: dendritic cells (DCs), which serve as professional antigen-presenting cells to prime the patient's immune system; Precision Multiple Antigen-Targeted (PMAT) T cells; and Precision Natural Killer/T (PNAT) cells. PMAT and PNAT cells are ex-vivo expanded and activated effector cells designed to recognize and eliminate malignant cells expressing a broad spectrum of tumor-associated antigens. In clinical practice, this "Precision Cell" cocktail is typically administered in combination with transarterial chemoembolization (TACE), where TACE provides local tumor debulking and antigen release, while the immunotherapy provides a systemic, targeted immune response to control residual disease and prevent recurrence.
- Other names
- Precision CellsDC-PMAT-PNAT therapyPrecision Cell therapy
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on Precision Cell Immunotherapy (Ningbo Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Cell Immunotherapy (Ningbo Cancer Hospital).